Xiaoqing Wang

Dr. Xiaoqing Wang

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
JTJing-Yan Tian
Jing-Yan Tian
CCChang-Liang Chi
Chang-Liang Chi
GBGe Bian
Ge Bian
DXDong Xing
Dong Xing
FGFeng-Jun Guo
Feng-Jun Guo
XWXiaoqing Wang
Xiaoqing Wang

31 August 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
QTQinyuan Tan
Qinyuan Tan
HLHanxiang Le
Hanxiang Le
CTChao Tang
Chao Tang
MZMing Zhang
Ming Zhang
WYWeijie Yang
Weijie Yang
XWXiaoqing Wang
Xiaoqing Wang
Injuries to the urethra can be caused by malformations, trauma, inflammation, or carcinoma, and reconstruction of the injured urethra is still a significant challenge in clinical urology. Implanting grafts for urethroplasty and end-to-end anastomosis are typical clinical interventions for urethral injury. However, complications and high recurrence rates remain unsatisfactory. To address this, urethral tissue engineering provides a promising modality for urethral repair. Additionally, developing tailor-made biomimetic natural and synthetic grafts is of great significance for urethral reconstruction. In this work, tailor-made biomimetic natural and synthetic grafts are divided into scaffold-free and scaffolded grafts according to their structures, and the influence of different graft structures on urethral reconstruction is discussed. In addition, future development and potential clinical application strategies of future urethral reconstruction grafts are predicted.

17 March 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HSHongli Shan
Hongli Shan
ZCZhongshuai Cao
Zhongshuai Cao
CCChangliang Chi
Changliang Chi
JWJixue Wang
Jixue Wang
XWXiaoqing Wang
Xiaoqing Wang
BYBing Yu
Bing Yu
Drug eluting ureteral stent is an effective means for local drug delivery to the urinary tract. It can potentially solve a variety of upper urinary tract problems, such as stent-related urinary tract infections and discomfort, ureteral stricture, and neoplastic diseases. However, the release of drug elutes on the surface of biostable stents is unsustainable and uncontrollable. With the development of biomaterial science, the emergence of biodegradable ureteral stents (BUSs) provides a new approach for local drug delivery in the urinary tract. The drugs can be continuously released in a controlled manner from a drug-eluting BUS, when the stent degrades. Especially for the delivery of anti-tumor drugs, the stents can obviously improve the therapeutic effectiveness of the drugs by prolonging the contact duration of the drug and tumor cells. In addition, a secondary stent removal procedure can be avoided. The purpose of this review article is to provide an overview of anti-tumor drug-eluting BUSs and discuss the biomaterials and drug delivery systems of BUS that are currently being developed to deliver anti-tumor drugs for upper tract urothelial carcinoma.

12 August 1999 in Langmuir
Verified
Journal Article
Closed access
JJJian Jin
Jian Jin
LLLin Song Li
Lin Song Li
XWXiaoqing Wang
Xiaoqing Wang
YLYi Li
Yi Li
YZYan Jie Zhang
Yan Jie Zhang
TLTie Jin Li
Tie Jin Li

1 December 2019 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
SLShuai Lin
Shuai Lin
JSJun Shen
Jun Shen
ZWZhao Wanjun
Zhao Wanjun
XWXiaofei Wang
Xiaofei Wang
XWXiaoqing Wang
Xiaoqing Wang
JZJingqiang Zhu
Jingqiang Zhu
Background: At present, most of the targeted therapies for thyroid carcinoma are in the clinical trial stage, and there is still no strong evidence to confirm their clinical effect. The aim of this meta-analysis was to evaluate the outcome of targeted therapies and provide quantitative evidence. Method: Ovid, PubMed, EMBAS, ClinicalTrails.gov, and Cochrane Library electronic databases were searched until September 1, 2019. Randomized controlled studies (RCTs) studies that compared the treatment of thyroid carcinoma with the targeted therapies of utility and complications were analyzed. Results: The study included 5 studies with a total of 1,615 patients, with 991 cases in the drug group and 624 cases in the placebo group. The meta-analysis indicated that compared with the placebo group, the progression-free survival (PFS) rate of the drug group was significantly improved. The PFS of the drug group was 10.8 to 30.5 months, compared with 4 to 19.3 months for the placebo group (6 months PFS: OR =3.23, 95% CI: 2.57 to 4.05, P<0.00001, 12 months PFS: OR =3.38, 95% CI: 2.58 to 4.42, P<0.00001, 18 months PFS: OR =2.48, 95% CI: 1.74 to 3.54, P<0.00001). Overall survival (OS) did not differ significantly in the study (6 months: OR =1.53, 95% CI: 1.00 to 2.35, P=0.05, 12 months: OR =1.26, 95% CI: 0.94 to 1.69, P=0.12, 18 months: OR =1.11, 95% CI: 0.87 to 1.42, P=0.39). The incidence of adverse reactions in the drug group was significantly higher than that in the placebo group (OR =4.76, 95% CI: 3.45 to 6.57, P<0.00001), and the subgroup of adverse reactions was still significantly higher than that in the placebo group. Conclusions: This meta-analysis revealed that the targeted drugs can significantly prolong PFS in patients with thyroid carcinoma, but the targeted drugs did not prolong the OS. Although the incidence of adverse reactions was significantly higher than that of the placebo group, the patients were still tolerable in drug group.

25 September 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
MCMingyang Chang
Mingyang Chang
CCChangliang Chi
Changliang Chi
ZZZuozhu Zheng
Zuozhu Zheng
MZMing Zhang
Ming Zhang
JLJianing Lv
Jianing Lv
XWXiaoqing Wang
Xiaoqing Wang
Drug infusion therapy after surgery for urothelial carcinoma is an effective measure to reduce cancer recurrence rate. Hydrogels are drug carriers with good biocompatibility and high drug loading capacity, which can optimize the pharmacokinetics of drugs in the urinary system to improve the therapeutic effect. Compared with the traditional free drug in situ perfusion, the hydrogel drug loading system can still maintain effective drug concentration in the face of continuous urinary flushing due to its good mucosal adhesion effect. The significantly prolonged drug retention time can not only improve the therapeutic effect of drugs, but also reduce the discomfort and risk of urinary tract infections caused by frequent drug infusion, and improve patient compliance. In addition, the combination of hydrogel with nanoparticles and magnetic materials can also improve the mucosal permeability and targeting effect of the hydrogel drug loading system, so as to overcome the mucus layer of urinary epithelium and the physiological barrier of tumor and minimize the impact on normal tissue and cell functions. At present, the research of hydrogels for urothelial cancer treatment involves chemotherapy, immunotherapy, gene therapy, inhibition of metabolism and multi strategy synergistic therapy. This review summarizes the research progress of hydrogels for the treatment of urothelial carcinoma, hoping to provide a reference for the future research of safe, reliable, effective, and advanced hydrogels with little side effects.